Kennedy Capital Management LLC Purchases Shares of 2,675 Stryker Co. (NYSE:SYK)

Kennedy Capital Management LLC purchased a new stake in shares of Stryker Co. (NYSE:SYK) during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 2,675 shares of the medical technology company’s stock, valued at approximately $957,000.

Other large investors have also recently made changes to their positions in the company. Aspen Investment Management Inc raised its stake in shares of Stryker by 0.7% in the first quarter. Aspen Investment Management Inc now owns 4,368 shares of the medical technology company’s stock worth $1,563,000 after purchasing an additional 31 shares during the last quarter. Harbor Investment Advisory LLC increased its holdings in Stryker by 0.4% in the 1st quarter. Harbor Investment Advisory LLC now owns 6,982 shares of the medical technology company’s stock worth $2,499,000 after acquiring an additional 31 shares in the last quarter. Proficio Capital Partners LLC raised its position in Stryker by 2.4% during the first quarter. Proficio Capital Partners LLC now owns 1,418 shares of the medical technology company’s stock worth $507,000 after acquiring an additional 33 shares during the period. Consolidated Portfolio Review Corp lifted its position in shares of Stryker by 3.6% in the fourth quarter. Consolidated Portfolio Review Corp now owns 983 shares of the medical technology company’s stock valued at $294,000 after acquiring an additional 34 shares in the last quarter. Finally, FourThought Financial Partners LLC boosted its stake in shares of Stryker by 3.3% in the fourth quarter. FourThought Financial Partners LLC now owns 1,076 shares of the medical technology company’s stock worth $322,000 after acquiring an additional 34 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Trading Down 0.8 %

Shares of Stryker stock opened at $327.45 on Thursday. The company’s fifty day moving average is $338.89 and its two-hundred day moving average is $339.52. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.99 and a current ratio of 1.71. The company has a market capitalization of $124.74 billion, a P/E ratio of 37.38, a PEG ratio of 2.60 and a beta of 0.89.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, July 30th. The medical technology company reported $2.81 earnings per share for the quarter, topping analysts’ consensus estimates of $2.79 by $0.02. Stryker had a return on equity of 23.26% and a net margin of 16.12%. The company had revenue of $5.42 billion during the quarter, compared to analysts’ expectations of $5.40 billion. During the same period last year, the firm earned $2.54 EPS. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. Analysts forecast that Stryker Co. will post 11.95 earnings per share for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 31st. Stockholders of record on Friday, June 28th were issued a $0.80 dividend. This represents a $3.20 annualized dividend and a dividend yield of 0.98%. The ex-dividend date was Friday, June 28th. Stryker’s payout ratio is 36.53%.

Analysts Set New Price Targets

SYK has been the topic of several recent research reports. UBS Group lifted their target price on shares of Stryker from $351.00 to $366.00 and gave the stock a “neutral” rating in a research note on Wednesday. Morgan Stanley raised their price target on shares of Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a report on Monday, July 15th. Robert W. Baird upped their price objective on Stryker from $367.00 to $378.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. TD Cowen lifted their target price on Stryker from $365.00 to $400.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Stifel Nicolaus cut their price objective on Stryker from $375.00 to $365.00 and set a “buy” rating for the company in a research report on Wednesday. Four analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $371.74.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.